Next Article in Journal
Sinulariolide Inhibits Gastric Cancer Cell Migration and Invasion through Downregulation of the EMT Process and Suppression of FAK/PI3K/AKT/mTOR and MAPKs Signaling Pathways
Next Article in Special Issue
The Pharmacokinetics of Fucoidan after Topical Application to Rats
Previous Article in Journal
α-Glucosidase Inhibition and Molecular Docking Studies of Natural Brominated Metabolites from Marine Macro Brown Alga Dictyopteris hoytii
Previous Article in Special Issue
Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach
Open AccessArticle

Toxicity, Pharmacokinetics, and Gut Microbiome of Oral Administration of Sesterterpene MHO7 Derived from a Marine Fungus

Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, and Wuhan University School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
Author to whom correspondence should be addressed.
Mar. Drugs 2019, 17(12), 667;
Received: 10 October 2019 / Revised: 25 November 2019 / Accepted: 25 November 2019 / Published: 26 November 2019
(This article belongs to the Special Issue Pharmacokinetic Research of Marine Drugs)
Sesterterpene MHO7 derived from mangrove fungus is a novel estrogen receptor degrader for the treatment of breast cancer. To explore its safety and pharmacokinetics in vivo, Log P/D values, stability in simulated gastric/intestinal (SGF/SIF), toxicity, and pharmacokinetics studies were carried mainly by liquid chromatography technique coupled with tandem mass spectrometry (LC–MS/MS) method in mice, and the effect of MHO7 on mice gut microbiota at different time points was revealed by 16S rRNA sequencing. Log P/D values ranged 0.93–2.48, and the compound in SGF and SIF is stable under the concentration of 5 mM·L1. The maximum tolerance dose (MTD) of oral administration in mice was 2400 mg·kg1. The main pharmacokinetics parameters were as following: Cmax of 1.38 μg·mL1, Tmax of 8 h, a half-life (t1/2) of 6.97 h, an apparent volume of mean residual time (MRT) of 8.76 h, and an area under the curve (AUC) of 10.50 h·μg·mL1. MHO7 displayed a wide tissue distribution in mice, with most of the compound in liver (3.01 ± 1.53 μg·g1) at 1 h, then in fat (5.20 ± 3.47 μg·g1) at 4 h, and followed by reproductive organs with the concentrations of 23.90 ± 11.33 μg·g1,13.69 ± 10.29 μg·g1, 1.46 ± 1.23 μg·g1, and 0.36 ± 0.46 μg·g1 at 8, 12, 20 and 30 h, respectively. The most influenced genera of gut microbiome belonged to phylum Firmicutes (21 of 28), among which 18 genera originated from the order Clostridiales, class Clostridia, and families of Ruminococcaceae (11 of 18) and Lachnospiraceae (4 of 18). These results provide that MHO7 is suitable for oral administration in the treatment of breast cancer with the target organs of reproductive organs and regulation on Ruminococcaceae and Lachnospiraceae.
Keywords: MHO7; Log P/D values; Toxicity; Pharmacokinetics; Gut microbiome MHO7; Log P/D values; Toxicity; Pharmacokinetics; Gut microbiome
MDPI and ACS Style

Tian, W.; Yang, L.; Wu, D.; Deng, Z.; Hong, K. Toxicity, Pharmacokinetics, and Gut Microbiome of Oral Administration of Sesterterpene MHO7 Derived from a Marine Fungus. Mar. Drugs 2019, 17, 667.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop